Results 121 to 130 of about 44,923 (207)

Irinotecan-Loaded Vaterite Microspheres for Drug Delivery: Drug Release and Dissolution Kinetics and Mechanism in an Aqueous Solution and Human Serum. [PDF]

Langmuir
Milner MP, Saint HA, Yang JM, Neumann CCM, Wansch K, Compton RG.   +5 more
europepmc   +1 more source

Incidence and outcomes of postoperative paralytic ileus after cytoreductive surgery with HIPEC: A population‐based study

Colorectal Disease, Volume 28, Issue 8, August 2026.
Abstract Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is standard treatment for peritoneal metastases in Sweden. Prolonged postoperative ileus (PPOI) is a common complication following major abdominal surgery and is associated with increased morbidity and prolonged hospitalization.
Lana Ghanipour, Lana Othman Mahmmud, Biying Huang, Gabriella Jansson Palmer, Peter Cashin, Mirna Abraham‐Nordling   +5 more
wiley   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah, Werner Dammermann, Stefan Lueth   +2 more
wiley   +1 more source

Impact of <i>UGT1A1*28</i> polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. [PDF]

Future Oncol
Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A.   +10 more
europepmc   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Long-term survival in metastatic abdominal Ewing sarcoma with gastric serosal involvement following first-line irinotecan plus cisplatin: a case report. [PDF]

Front Oncol
Ji L, Li Y, Chen X, Liu Y, Tao W, Wang G, Cui T, Chen Y, Sun H, Jiang N, Wang K.   +10 more
europepmc   +1 more source

Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect. [PDF]

Blood Lymphat Cancer
Medrano-Villagómez CA, Loredo-García E, Gasperin-Bulbarela J, Vazquez-Duhalt R.   +3 more
europepmc   +1 more source

Association Between Irinotecan-Containing Regimens and Functional and Nutritional Impairment in Advanced Colorectal Cancer: An Exploratory PG-SGA Analysis. [PDF]

Cancers (Basel)
Guerrero-Martín J, Macias-Montero R, Macías-Gañán Y, Araujo-Blesa M, Paniagua-Vivas MS, Sánchez-Diestro LE.   +5 more
europepmc   +1 more source

Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer. [PDF]

ESMO Open
van Eekelen R, Punt CJA, Kwakman JJM, Coupé VMH.   +3 more
europepmc   +1 more source